ETF Holdings Breakdown of SRPT

Stock Name	Sarepta Therapeutics Inc
Ticker	SRPT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8036071004
LEI	549300IKDPIED8J8IG21

SRPT institutional holdings

The following institutional investment holdings of SRPT have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2026-01-15 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 1,515 2.8% USD 32,285 -4.0% 21.31

2026-01-15 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 598 USD 12,743 -7.0% 21.31

2026-01-15 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 38,275 15.4% USD 815,640 9.4% 21.31

2026-01-15 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 72,972 0.5% USD 1,555,033 -6.5% 21.31

2026-01-15 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 82,207 USD 1,751,831 -7.0% 21.31

2026-01-15 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 72,972 0.5% USD 1,555,033 -6.5% 21.31

2026-01-15 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 121,806 USD 2,595,686 -7.0% 21.31

Total = 390,345 USD 8,318,251
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2026-01-15	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,515 2.8%	USD 32,285 -4.0%	21.31
2026-01-15	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	598	USD 12,743 -7.0%	21.31
2026-01-15	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	38,275 15.4%	USD 815,640 9.4%	21.31
2026-01-15	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	72,972 0.5%	USD 1,555,033 -6.5%	21.31
2026-01-15	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	82,207	USD 1,751,831 -7.0%	21.31
2026-01-15	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	72,972 0.5%	USD 1,555,033 -6.5%	21.31
2026-01-15	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	121,806	USD 2,595,686 -7.0%	21.31
Total =	390,345	USD 8,318,251

News associated with SRPT

Leerink Partners Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target raised by analysts at Leerink Partners from $12.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. Leerink Partners’ price target would indicate a potential downside of 12.89% from the stock’s […] - 2025-09-11 03:04:49
After Hours Most Active for Aug 29, 2025 : ELAN, NVDA, GOOG, PPBI, SRPT, COLB, MSFT, SNAP, KMI, XOM, NEE, PFE: The NASDAQ 100 After Hours Indicator is down -7.17 to 23,408.25. The total After hours volume is currently 173,977,891 shares traded.The following are the most active stocks for the after hours session: Elanco Animal Health Incorporated (ELAN) is unchanged at $18.35, with 22,912 - 2025-08-29 17:29:12
HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. A number of other research firms have also issued reports on SRPT. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and […] - 2025-08-27 02:30:45
Sarepta Therapeutics (NASDAQ:SRPT) Given New $17.00 Price Target at Bank of America: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lifted by Bank of America to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have an underperform rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the company. Baird R W lowered Sarepta Therapeutics from […] - 2025-08-21 04:58:48
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $12.00: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective hoisted by Deutsche Bank Aktiengesellschaft to $12.00 in a research note released on Friday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. TD Cowen lowered shares of Sarepta Therapeutics […] - 2025-08-18 03:06:45
Vanguard Group Inc. Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Vanguard Group Inc. lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 9,032,613 shares of the biotechnology company’s stock after selling 52,843 shares during the quarter. Vanguard Group Inc. owned about 0.09% […] - 2025-08-14 04:37:10
Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to “Equal Weight”: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price objective indicates a potential upside […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Barclays: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by research analysts at Barclays from an “underweight” rating to an “equal weight” rating in a report released on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price target would indicate a potential upside of 35.38% […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Equal Weight at Barclays: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by stock analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports. The brokerage presently has a $22.00 price target on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 31.34% […] - 2025-07-31 05:26:59
BMO Capital Markets Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target hoisted by BMO Capital Markets from $25.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 198.51% from the stock’s […] - 2025-07-31 05:26:58
William Blair Reaffirms “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Tuesday,RTT News reports. Other equities analysts have also recently issued reports about the stock. Bank of America reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on […] - 2025-07-31 05:26:58
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective hoisted by equities researchers at Morgan Stanley from $15.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 19.40% from the stock’s […] - 2025-07-31 03:02:52
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, MarketBeat.com reports. A number of other equities research analysts also recently commented on SRPT. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $32.00 to $18.00 […] - 2025-07-31 03:02:51
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by JPMorgan Chase & Co.: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by equities researchers at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $24.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target […] - 2025-07-31 03:02:51
Sarepta Therapeutics (NASDAQ:SRPT) Earns “Underperform” Rating from Needham & Company LLC: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “underperform” rating reaffirmed by Needham & Company LLC in a report issued on Monday,Benzinga reports. Several other equities analysts have also recently issued reports on SRPT. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price […] - 2025-07-30 04:54:53
Barclays Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to Strong Sell: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Barclays from a “hold” rating to a “strong sell” rating in a report released on Monday, MarketBeat Ratings reports. Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta […] - 2025-07-30 04:54:51
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade: Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) shares gapped up before the market opened on Tuesday after Barclays upgraded the stock from an underweight rating to an equal weight rating. The stock had previously closed at $13.86, but opened at $18.23. Barclays now has a $22.00 price target on the stock. Sarepta Therapeutics shares […] - 2025-07-30 02:14:47
Pre-Market Most Active for Jul 29, 2025 : NVO, SOFI, TSLL, SRPT, SQQQ, NVDA, SNAP, OPEN, UNH, NU, KVUE, T: The NASDAQ 100 Pre-Market Indicator is up 88.72 to 23,444.99. The total Pre-Market volume is currently 249,308,466 shares traded.The following are the most active stocks for the pre-market session: Novo Nordisk A/S (NVO) is -13 at $56.00, with 18,349,390 shares traded. NVO's cur - 2025-07-29 09:29:58
JPMorgan Chase & Co. Reiterates “Underweight” Rating for Sarepta Therapeutics (NASDAQ:SRPT): JPMorgan Chase & Co. reaffirmed their underweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report published on Friday morning, Marketbeat Ratings reports. Other equities research analysts have also recently issued research reports about the company. BMO Capital Markets dropped their price target on Sarepta Therapeutics from $70.00 to $50.00 and […] - 2025-07-28 04:42:50
Victory Capital Management Inc. Has $4.32 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Victory Capital Management Inc. decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,712 shares of the biotechnology company’s stock after selling 21,096 shares during […] - 2025-07-27 09:30:47
Sarepta Therapeutics Accepts CHMP's Negative Opinion For ELEVIDYS: (RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Friday acknowledged the Committee for Medicinal Products for Human Use's negative opinion on the conditional marketing authorization for ELEVIDYS in ambulatory individuals ages three to seven years for the treatment of Duchenne muscu - 2025-07-25 10:18:38
Sarepta Therapeutics (NASDAQ:SRPT) Lowered to “Hold” Rating by Barclays: Barclays downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) from a strong-buy rating to a hold rating in a research note published on Tuesday, MarketBeat reports. They currently have $18.00 price objective on the biotechnology company’s stock. A number of other analysts also recently issued reports on the stock. The Goldman Sachs Group downgraded […] - 2025-07-25 04:59:01
Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $56.50: Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has earned a consensus rating of “Hold” from the twenty-eight research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and eight have issued a buy rating on the […] - 2025-07-23 05:10:52
Sarepta Therapeutics (NASDAQ:SRPT) Receives “Hold” Rating from Deutsche Bank Aktiengesellschaft: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Monday, Marketbeat reports. Several other equities analysts have also issued reports on the stock. Mizuho restated a “neutral” rating and issued a $14.00 target price (down previously […] - 2025-07-22 07:13:02
Sarepta Therapeutics (NASDAQ:SRPT) Receives “Market Perform” Rating from Leerink Partners: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “market perform” rating reissued by research analysts at Leerink Partners in a research note issued on Monday, MarketBeat reports. A number of other equities analysts have also issued reports on SRPT. Oppenheimer reduced their target price on Sarepta Therapeutics from $45.00 to $41.00 and set […] - 2025-07-22 07:13:02
Sarepta Therapeutics (NASDAQ:SRPT) Earns Market Perform Rating from Leerink Partners: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “market perform” rating reiterated by Leerink Partners in a note issued to investors on Monday, Marketbeat reports. SRPT has been the subject of a number of other reports. JPMorgan Chase & Co. cut their price target on Sarepta Therapeutics from $28.00 to $20.00 and set […] - 2025-07-22 07:13:02
Sarepta Therapeutics (NASDAQ:SRPT) Earns “Hold” Rating from Deutsche Bank Aktiengesellschaft: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “hold” rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Monday, MarketBeat.com reports. Several other research analysts also recently commented on SRPT. Bank of America dropped their target price on shares of Sarepta Therapeutics from $28.00 to $20.00 and […] - 2025-07-22 07:13:02
Piper Sandler Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective decreased by Piper Sandler from $32.00 to $18.00 in a research report sent to investors on Monday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock. A number of other research analysts have also issued reports on SRPT. TD Cowen […] - 2025-07-22 07:12:59
JPMorgan Chase & Co. Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective cut by JPMorgan Chase & Co. from $28.00 to $20.00 in a report issued on Monday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. SRPT has been the topic of several other reports. Mizuho reduced their price objective on Sarepta […] - 2025-07-22 04:32:46
Pre-Market Most Active for Jul 18, 2025 : BZAI, LCID, SRPT, TSLL, BBAI, QS, ETHA, SQQQ, JOBY, ACHR, BABA, NIO: The NASDAQ 100 Pre-Market Indicator is up 25.99 to 23,107.04. The total Pre-Market volume is currently 137,099,362 shares traded.The following are the most active stocks for the pre-market session: Blaize Holdings, Inc. (BZAI) is +2.76 at $5.79, with 28,363,967 shares traded. As - 2025-07-18 09:29:55

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.